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14 June 2019 
Dear Home Secretary,  
Re: ACMD report - Ageing cohort of drug users   
In recent years, statistics have been published to show a demonstrable shift in age 
profile of individuals accessing treatment for drug use in the UK. In response to this 
the Advisory Council on the Misuse of Drugs (ACMD) undertook this self-
commissioned report to review the evidence of this trend and assess the implications 
of an ageing cohort on specialist drug treatment services.  
In this report, the ACMD describes the changing age profile; provides an overview of 
the challenges faced by this ageing cohort in the UK; explains why current service 
regimen are not meeting the needs of this group and makes recommendations for 
practise and policy. 
The ACMD concluded that this ageing cohort of drug users (those over the age of 35 
years) now account for a significant proportion of patients in specialist community drug 
treatment services. Many substance misuse services in the UK do not adequately 
cater to the needs of this cohort and services will need to adapt to fit to this permitting 
trend. 
 
Conclusions  
 
o Specialist community drug services are treating an ageing cohort of patients. 
Predominant among these are those with problematic opiate/opioid use.  
 
o Research suggests that older drugs users, particularly opiate/opioid users, have 
multiple additional risk factors resulting from their deteriorating physical and mental 
health, difficulty in navigating complex health and social care systems and 
experience of stigma. 
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o There are indications which suggest that addressing the complex and varied needs 
of older opiate/opioid users will increasingly become a mainstream treatment 
activity. 
 
o Specialist community drug services are insufficiently prepared to manage the 
complex needs of this ageing cohort, despite the increase in older drug users 
attending for treatment.  
 
o Commissioners, providers and the specialist drug treatment workforce all need to 
ensure that staff are competent to meet these demands with the expected increase 
in complexity of treatment required by attendees.  
 
o Future trends in treatment presentations of ageing cohorts are difficult to predict 
and careful monitoring of drug treatment populations and other metrics of drug 
misuse should be explored and utilised. The better recording of prevalence of 
substance misuse by ageing drug users will improve understanding of the ageing 
treatment cohort and support service planning and delivery. 
 
Recommendations 
 
• Specialist community-based drug treatment services should develop training for 
staff to highlight the treatments and specific risks for older drug users, particularly 
opiate/opioid users.  
 
• Given the changes to the specialist community drug treatment workforce over the 
last five years, an assessment should be conducted of the current range and 
availability of skills, treatment and support available to people presenting to 
treatment. A particular focus should be the availability and knowledge of staff to 
address the complex physical and mental health issues of older drug users. 
 
• An evaluated pilot programme to determine whether the use of the service 
navigator model will assist older drug users to engage more successfully in 
complex health and social care systems, improve the quality of care and health 
outcomes and be cost effective. 
 
• Close and ongoing analysis of treatment presentation data and wider metrics of 
drug misusing patterns, with particular attention given to refining and standardising 
age categories.  
 
We welcome the opportunity to discuss and present this report to the Drug Strategy 
Board.  
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Yours sincerely,  
 
 
 
Dr Owen Bowden-Jones   Dr Kostas Agath 
Chair of ACMD    Chair, ACMD Ageing cohort working group 
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1. Introduction 
1.1. The past decade has seen a demonstrable shift in the age profile of individuals accessing 
treatment for drug use. An ageing cohort, who have survived lengthy histories of heavy drug 
use, now account for an increasing proportion of those in specialist community drug treatment 
in the UK and in Europe. Ageing added to the effects of long-term heavy drug use means that 
this cohort is now experiencing a range of issues, including deteriorating physical and mental 
health. Many substance misuse services in the UK do not cater adequately to the needs of this 
cohort, meaning that ageing drug users may feel disengaged and fall out of treatment or be 
perceived and/or actually judged as unsuitable.  
 
1.2. Those ageing in community drug treatment services are most likely to be using opiates/opioids. 
Since the 1970s, problem opiate/opioid users (often injectors) in the UK have represented the 
largest group receiving specialised drug treatment. More recently, the number of opioid users 
entering treatment across the EU has declined, while the average age of those retained in 
treatment has increased. High-risk drug users aged over 40 may soon become the largest drug 
treatment population in Europe (EMCDDA, 2017). The impact of these demographic changes has 
only recently been recognised. The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) has suggested that addiction services and other healthcare services have been 
insufficiently aware of the specific needs of the ageing cohort of drug users and they continue to 
need to prepare for increases in demand from this age group (EMCDDA, 2008; 2010). 
 
1.3. This report from the Advisory Council on the Misuse of Drugs (ACMD) aims to describe the 
changing age profile of people accessing drug treatment, provide an overview of the challenges 
faced by the ageing cohort in the UK, explain why current service regimens are not meeting the 
needs of this group and make recommendations for practise and policy. 
 
1.4. This report will focus on those attending specialist drug treatment services for treatment of 
illicit drug use. The report will not consider:  
 
• drug users outside treatment services;  
• the misuse of prescription medication; or,  
• primary alcohol users. 
 
1.5. For the purposes of this report:  
• the ageing cohort is considered to be those aged over 35 years. 
• the term ‘substance misuse service’ will be used to describe treatment services in 
general.  
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2. Treatment statistics indicating a changing profile 
2.1. Specialist drug treatment data have charted a looming challenge with increases in the number 
of older drug users receiving treatment.i The ageing cohort we focus on is characterised by 
problematic opiate/opioid use. Available data show a substantial, consistent, year-on-year 
increase in the number of treated opiate users who are over the age of 40: this number almost 
tripled, from around 26,000 in 2005/06 to around 75,000 in 2017/18 (see Figure 1).  
 
2.2. Figure 1 shows that the number of individuals in treatment for primary opiate problems under 
the age of 30 has declined substantially over the past decade (from around 55,000 to around 
13,000 (compiled by a working group from PHE, NDTMS data). 
 
Figure 1: Number of opiate users in treatment in England, by age group and year of treatment: 
2005/06 to 2017/18 (PHE, NDTMS data)   
 
2.3. Figure 2 shows the change in age distribution of treated opiate users from 2005/06 to 2017/18. 
By 2017/18, just 9% of treated opiate users were under the age of 30 years, 38% were in their 
30s, and 53% were over the age of 40. Notably, 16% were over the age of 50 (PHE, NDTMS data). 
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Figure 2: Comparison of the age distribution of treated opiate users in 2005/06 and 2017/18 
(PHE, NDTMS data)  
 
2.4. These data suggest that an ageing, opiate-using cohort currently dominates demand for 
substance misuse services and this will continue into the future.  
 
2.5. Other groups engaging in substance misuse treatment include non-opiate drug users, non-opiate 
and alcohol users and alcohol only users (see Table 1), Younger people account for a larger 
proportion of these groups than is the case for primary opiate users in treatment.  It is not clear 
whether drug use within this group will persist with age to the same degree as has been observed 
for opiate users.  
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Table 1: Age and substance use of all individuals in substance misuse treatment in England: 
2017/181 
 
 
2.6. In England: Figure 3 shows a marked geographical variation in the age distribution of opiate users 
in treatment across England (see Figure 3). Although estimates of the prevalence of opiate misuse 
in England do indicate a declining population, the decline has, hitherto, been rather modest:  
• from circa 281,000 individuals in 2004/5 (95% CI 280,000 to 293,000);  
• to 261,000 in 2016/17 (95% CI 259,000 to 271,000).  
(Liverpool John Moores University; UK Focal Point on Drugs, 2017).2   
 
2.7. These prevalence estimates also indicate that an increasing proportion, and number, of opiate 
users are over the age of 35 years. Table 1 shows the age distribution of all individuals in substance 
misuse treatment in 2017/18. The estimates currently are commissioned on the basis of reporting 
prevalence for the age groups 15-24, 25-34 and 35-64 years. Given the increasing concern 
regarding this ageing cohort of drug users, it may be advisable to review the age categories on 
which these estimates are produced. That is, to divide the category 35-64 into more specific age-
ranges such as 35-44, 45-54, 55-64.   
 
 
 
 
                                            
1 Reproduced from Public Health England (2016) ‘Adult substance misuse statistics from the National Drug 
Treatment Monitoring System (NDTMS): 1st April 2015 - 31st March 2016’ 
 
2 https://phi.ljmu.ac.uk/wp-content/uploads/2019/03/Estimates-of-the-Prevalence-of-Opiate-Use-and-or-
Crack-Cocaine-Use-2016-17-Sweep-13-report.pdf  
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Figure 3: Percentage of opiate users aged 35 and over in treatment, by local authority area. (NDTMS, 
2017/18)ii 
 
2.8. In Scotland: In 2015/16 it was estimated that over half of people with a drug problem in Scotland 
were over the age of 35. Among those seeking help from specialist drug treatment services, the 
percentage of individuals aged 35 and over increased from 29% in 2006/07 to 51% in 2016/17 
(ISD, 2019). A review of opioid substitution therapy (OST) in 2013, noted that the average age of 
those using substances had markedly increased. Given that ageing is associated with worsening 
health in general, the degree of both physiological and psychological difficulty, already high 
among those in OST, is likely to increase further (Independent expert review of opioid 
replacement therapies in Scotland, 2013). 
 
2.9. In Northern Ireland: The Northern Ireland Substance Misuse Database (SMD) records 
information on new presentations to treatment services with problem drug and/or alcohol use. 
As such, it is not possible to compare the Northern Ireland data to the England data.  For instance: 
(a) it is not possible to know the number of those over the age of 35 in the treatment system 
from the SMD data; (b) furthermore, the age breakdown by the number of new heroin users 
according to the SMD would not be comparable to the NDTMS, which reports heroin/opiate users 
in treatment.  In 2016/17, the SMD recorded a total of 4,368 clients presented to services with 
problem drug misuse in Northern Ireland, of which approximately 10% reported heroin use 
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(Northern Ireland Substance Misuse Database, 2017). The majority of those reporting heroin use 
(approximately 80%) were aged under 40, which could suggest differences in the age profile of 
opiate users in Northern Ireland compared to the rest of the United Kingdom.     
 
2.10. In Wales: In 2017, the Advisory Panel on Substance Misuse (APoSM) had found that the 
population in treatment for substance misuse problems was ageing and that substance misuse 
among older adults was a significant and growing problem (APoSM, 2017).  
 
2.11. Across the UK, with the exception of Northern Ireland, treatment services are characterised 
by an ageing population of opiate users who have remained periodically in contact with agencies 
but have struggled to achieve sustained abstinence from opiate use. It is likely that this is a 
reflection of the clinical nature of opiate dependence, with periods of relapse and remission 
continuing over many years. The patterns for other drug use are less clear. 
 
 
Likely development of UK drug treatment population over time  
2.12. As this cohort ages, some will recover, achieve sustained abstinence and exit specialist 
treatment services. Some people will die as a direct or indirect consequence of their drug use or 
other age-related conditions. Over time, it might be expected that the older opiate-misusing 
treatment population will reduce in size, but those still in treatment will have increasingly 
complex physical, psychological and social needs. 
 
2.13. This expectation is supported by PHE projections in 2017. These suggested that, whilst the 
number of opiate users in treatment was likely to decline, by 2018:  
• around three-quarters of this group would be aged 40 years or more;  
• a third would be aged 50 years or more; and,  
• around three fifths of treated opiate users would have been using for 20 years or more.  
(Burkinshaw et al. 2017).  
Moreover, this PHE analysis of National Drug Treatment Monitoring System (NDTMS) data 
indicates that the likelihood of successfully completing treatment deteriorates with duration of 
use. 
 
2.14. It seems likely that this older population will have poor prospects of achieving permanent 
abstinence, although some may do so and this may continue to be the ultimate aim of treatment. 
Their need for stabilising substance misuse treatment will persist, as will the need to address 
increasing and premature age-related ill health. Therefore, unless there are dramatic and 
unexpected changes in this population, addressing the complex and varied needs of older 
opioid/opiate users will become the mainstream of treatment activity rather than a treatment 
specialism.  
 
2.15. In studies of older heroin users, high levels of physical, psychological and psychiatric 
comorbidities have been found (Rosen et al., 2011). Psychological problems can be severe and 
partly relate to trauma, bereavement and grief (Templeton et al., 2016). Problem drug use often 
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adds further trauma and life difficulties to pre-existing ones, which can escalate drug use further 
(Scottish Drugs Forum, 2013). 
 
2.16. A study by the Scottish Drugs Forum reported the biggest problems faced by older drug users 
compared with younger people as:  
• problems accumulated with age;  
• stigma;  
• feeling forgotten about; and,  
• lack of services.  
(Scottish Drugs Forum, 2017a; 2017b). 
 
3. Physical and mental health of ageing drug users   
3.1. Ageing opioid users suffer from accumulated physical impairments and have high levels of both 
physical and mental health problems (EMCDDA, 2010).  
 
3.2. Older problem drug users show a unique combination of features which present a challenge to 
health and care services. The chronic effects of problem drug use exacerbate and complicate the 
effects of ageing (Beynon, 2009). The ageing process itself is often associated with a range of 
psychological and physical health problems (Dowling et al., 2008). Drug intoxication and the 
residual effects of drug use may differ in older persons, affecting the cognitive, motor and 
physical functions of individuals. Individuals who have used drugs for many years are more likely 
to have poor general health related to physical functioning, role limitations due to physical health 
and bodily pain when compared with younger drug users and the general population (Lofwall et 
al., 2005).  
 
3.3. The cumulative effects of polydrug use, non-fatal overdose and infections over many years 
accelerate physical ageing among these users, with implications for treatment and social support 
services. 
 
3.4. Injecting drug users may already be stigmatised as undeserving or demanding and this situation 
is compounded among older, entrenched drug users with histories of poor treatment 
engagement (Lloyd, 2012, Simmonds et al. 2009, Neale et al. 2008).  
 
3.5. A UK study compared the characteristics of a group of patients aged over 50 years old entering a 
methadone maintenance programme for opioid dependence with those aged under 50 
(Badrakalimuthu et al., 2012). The study reported statistically higher rates of blood-borne viruses, 
physical and mental health morbidity in the 50 and over age group, compared with those aged 
under 50. Moreover, ageing drug users who had engaged in injecting behaviours over the course 
of their drug career may be at higher risk of having contracted and suffering the health 
consequences of Hepatitis C (HCV), which can take decades to manifest (Beynon 2009). The 
consequence of contracting HCV may only become apparent in later life with the onset of 
advanced liver disease. (Davis et al., 2010).iii Older adult methadone patients are likely to have 
accompanying mental health disorders (Rosen et al., 2011).  
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3.6. Emerging evidence highlights that the increase in fatal overdose risk faced by opioid users as they 
age may be specific to methadone (Gao et al., 2016; Pierce et al., 2018). That is, methadone may 
present particular risks to older users. In addition, the risk of a fatal overdose is observed to be 
greater among those who are in receipt of higher daily doses, so that older users who also receive 
the top quintile for daily-dose face dual risks.iv. Whilst it is vital to note that opioid substitution 
therapy (OST), in general terms, is highly protective against a fatal overdose (Pierce et al., 2016), 
there is a need to:  
• develop our understanding of methadone’s effects in older users; and,  
• for clinicians to monitor with particular care amongst older users the known risks of high-
dose methadone regarding QTc prolongation.  
 
Mortality and morbidity  
3.7. Drug use, particularly opioid/opiate use is associated with increased mortality and morbidity. 
Mortality rates in this ageing cohort of drug users are elevated and mortality risk accelerates with 
increasing age (Pierce et al., 2015). The ACMD reported on reducing opioid-related deaths in 
2016. 3 
 
                                            
3 Drug-related deaths (DRDs) have increased over the past 20 years, with significant increases in the numbers registered in the 
last 3 years among older heroin users, many of whom may have been in poor health after long periods of using the drug. The 
number of poisonings related to heroin use is also increasing, notably among older heroin users (Burkinshaw et al., 2017: 41). 
Those who are older and those with significant health problems, have a higher risk of premature mortality than the general 
population (ibid: 96). In 2013, the average age of those dying from a drug-related death was 41.6 years, with males tending to 
be about 5 years younger than females (40.5 years and 45.1 years, respectively). The median age at death increased from 32 
in 1999 to 41 in 2012.  The median age at death for women who suffered a drug misuse death was higher than for men (44 [in 
2012] compared with 39 in 2012), with the median age for both sexes generally increasing over the period. More than half of 
the nearly 3000 DRDs in England and Wales in 2013, and over 80% of nearly 500 DRDs in Scotland in 2012, involved opioids, 
and were predominantly overdoses (PHE, 2015). 
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Table 2: Cause-specific crude mortality rates (CMR) and standardised mortality ratios (SMR) for a 
cohort of 198,247 opioid users in England (Reproduced from Pierce et al (2015) Drug & Alcohol 
Dependence, 146, 17-23) 
 
Cause of Death and 
SMR linear trend by 
age group ni
CMR per 10k 
pys [95% CI] SMR [95% CI] n
i
CMR per 10k 
pys [95% CI] SMR [95% CI] n
i
CMR per 10k pys 
[95% CI] SMR [95% CI]
Infectious/parasitic 
diseases
23 0.8 [0.5, 1.2] 5.7 [3.8, 8.6] 56 3.2 [2.5, 4.1] 11.0 [8.5, 14.3] 80 11.7 [9.4, 14.6] 23.2 [18.6, 28.8]
 SMR trend p < 0.001
Cancers 33 1.1 [0.8, 1.6] 1.3 [0.9, 1.8] 72 4.1 [3.3, 5.2] 1.5 [1.2, 1.9] 191 28.0 [24.3, 32.2] 2.1 [1.8, 2.4]
 SMR trend p = 0.003
Circulatory system 71 2.4 [1.9, 3.0] 3.6 [2.9, 4.6] 143 8.1 [6.9, 9.6] 3.2 [2.7, 3.8] 204 29.9 [ 26.0, 34.3] 2.9 [2.5, 3.3]
 SMR trend p = 0.24
Respiratory system 40 1.3 [1.0, 1.8] 7.5 [5.5, 10.2] 88 5.0 [4.1, 6.2] 10.2 [8.3, 12.6] 131 19.2 [16.2, 22.8] 8.7 [7.3, 10.3]
 SMR trend p = 0.24
Digestive system 59 2.0 [1.5, 2.6] 5.8 [4.5, 7.5] 164 9.3 [8.0, 10.9] 6.0 [5.1, 6.9] 200 29.3 [25.5, 33.6] 7.1 [6.2, 8.2]
 SMR trend p = 0.16
Diseases of Liver: 44 1.5 [1.1,2.0] 6.4 [4.7, 8.5] 136 7.8 [6.6, 9.2] 6.3 [5.3, 7.4] 165 24.2 [20.7, 28.1] 7.9 [6.8, 9.2]
 SMR trend p = 0.10
Alcoholic liver 
disease
35 1.1 [0.8, 1.6] 6.8 [4.9, 9.4] 105 6.0 [4.9, 7.2] 6.4 [5.3, 7.7] 109 16.0 [13.2, 19.3] 7.1 [5.9, 8.5]
 SMR trend p = 0.75
Fibrosis and cirrhosis 
of liver 
2 0.1 [0.0, 0.3] 2.6 [0.7, 10.5] 18 1.0 [0.6, 1.6] 6.3 [3.9, 9.9] 46 6.7 [5.0, 9.0] 14.1 [10.6, 18.9]
 SMR trend p < 0.001
Homicides 35 1.2 [0.8, 1.6] 8.8 [6.3, 12.2] 28 1.6 [1.1, 2.3] 15.3 [10.7, 22.3] 14 2.0 [1.2, 3.5] 27.3 [16.1, 46.0]
 SMR trend p = 0.002
Suicides 93 3.1 [2.5, 3.8] 2.7 [2.2, 3.3] 79 4.5 [3.6, 5.6] 3.1 [2.5, 3.9] 27 4.0 [2.7, 5.8] 3.2 [2.2, 4.6]
 SMR trend p = 0.55
i number of observed deaths 
18 -34 years, (pys = 298,111) 35 - 44 years, (pys = 175, 464) 45 - 64 years, (pys = 68,317)
Age-group
 
Notes:  
SMR – standardised mortality ratio 
Pys - person years 
N – number of observed deaths 
CMR – crude mortality rate  
CI – confidence interval 
 
3.8. There are indications of certain types of deaths not related to opioid use being disproportionately 
high among this group compared with younger opioid users or same age non-drug using 
individuals. 4  
 
3.9. Older drug users in contact with treatment services were significantly more likely than younger 
drug users to die from causes that were not defined as drug-related (as shown in Table 2, see 
also Figures 4 and 5), where ‘drug related’ referred to acute drug toxicity and mental and 
behaviour disorders only (Beynon et al., 2010).  Kidney disease and diabetes may be more 
prevalent. Neurological and respiratory disorders, cancer and many other age-associated 
diseases may also be exacerbated by problem opioid use. Balance, coordination, vision and 
judgement may also be affected (Arona et al. 2015). Among the physical effects of long-term 
                                            
4 This applies to infectious diseases, cancers, liver cirrhosis and homicide – SMRs for these causes are statistically significantly 
higher with age. This does not apply to other causes (Pierce et al., 2015). 
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opioid use are the direct effects of intoxication, overdose and withdrawal, which can especially 
affect the liver, veins and lungs (ibid). 
 
O  
Figure 4: Crude mortality rate per 10,000 person-years, by cause and age (n= 198,247) (Findings from 
Pierce et al., (2015) Drug & Alcohol Dependence, 146, pp17-23) 
 
 
Figure 5: Standardised mortality ratio by cause and age (n= 198,247) (Findings from Pierce et al., 
(2015) Drug & Alcohol Dependence, 146, pp17-23)  
 
Existing policies  
3.10. Policies limiting the time that people are able to spend in treatment can be counter-
productive (PHE, 2013). While there is a need to maintain a realistic recovery ambition for ageing 
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heroin users with complex needs, it should be accepted that the proportion of these people who 
will successfully complete treatment is likely to continue to fall (ibid). The report concluded that:  
• they are more difficult to treat;  
• they have been with treatment services a long time;  
• they find it difficult to move on;  
• recovery is not an easy task;  
• they have entrenched problems;  
• they have failing health;  
• treatment may be a source of stability for them, which gives structure to their lives;  
• one quarter have been in treatment for five years or more, showing the benefits of 
methadone prescription; and,  
• dependence is hard to overcome.  
 
3.11. Each year, a proportion of the opiate treatment population makes the first steps towards 
recovery and abstinence, although the number completing treatment free of dependence has 
reduced since its peak (14,792 opiate users in 2011/12 compared with 9,309 in 2017/18 [PHE, 
NDTMS data]).  
 
3.12. PHE has previously recommended that national drug strategies should make explicit reference 
to the specific needs of the ageing cohort of drug users. They also recommended that all local 
authority, clinical commissioning groups and NHS Trust strategies that address the needs of older 
people should consider explicitly the needs of older people with a drug problem (Burkinshaw et 
al., 2017).  
 
3.13. It follows logically from the above observations, that it would make sense for existing 
mainstream drug services to adapt their provision to cater for the ageing cohort of drug users. In 
addition, specific innovative services could be set up, ideally with built-in evaluation.  
 
Challenges for treatment services   
3.14. There is rising concern about the lack of attention to substance use among older people (Royal 
College of Psychiatrists, 2011, 2018). This wider issue remains important and provides part of the 
context within which the specific question of the ageing cohort of drugs users should be 
addressed (EMCDDA, 2008; Beynon, 2009; DrugScope/Recovery Partnership 2014). 
  
3.15.  Community-based specialist drug services have experienced significant disinvestment and 
also experienced a loss of skilled staff (Finch et al., 2018; ACMD 2017). This is highly likely to 
impact on the capacity of the treatment system to undertake the type of complex interventions 
needed by an ageing cohort of opioid/opiate users. Concerns have been raised about the 
declining involvement of professionals in delivering community drug treatment services, 
especially addiction specialist doctors, psychologists, nurses, and social workers.v There is 
growing recognition among the workforce and stakeholders of increasingly complex needs in the 
service user population. The workforce that is needed should be ‘competent in identifying and 
responding to a wide range of health and social care needs and be able to support people to 
access treatment for co-existing physical and mental health issues’ (Public Health England/Royal 
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College of Nurses (RCN) 2017: 4). A series of briefings have been produced as a response to 
concerns raised by PHE stakeholders about reducing numbers of professional roles within alcohol 
and drug services, which reflect discussions and co-production with relevant stakeholders (BPS, 
2012; Galvani, 2015). The PHE/RCN briefing noted that ‘there is an ageing population of people 
accessing drug treatment services. Ageing and older service users tend to have more complex co-
morbidities and other health and social care related problems, and therefore nurses can 
potentially add value by offering the option of a ‘one stop shop’ for various physical, mental 
health and/or social care needs of older adults. This includes: providing advice on falls prevention; 
delivering interventions at an appropriate pace using modes of information that can overcome 
sensory and cognitive impairment; NHS health checks; testing for and providing advice on: 
chronic obstructive pulmonary disease (COPD); diabetes; ischaemic heart disease; hypertension; 
Parkinson’s disease; dementia; and helping people to access end of life care’ (PHE/RCN, 2017: 13-
14). 
 
3.16. It is therefore recognised that as this cohort ages further, it will require a set of costly and 
multi-disciplinary interventions beyond specialist drug treatment. Such measures do not appear 
to be in place at the levels required to meet the current and upcoming needs of this population 
(Pirona et al., 2016). Less successful outcomes in treatment populations is a particular concern 
for healthcare services.5 
 
3.17. It is likely that dual diagnosis/comorbidity patients in older age groups will present in 
increasing numbers to mental health professionals (Searby et al., 2014; Bartels et al., 2006; 
Kerfoot et al., 2011).  
 
3.18. A joined-up treatment and care approach with effective inter-agency partnerships and referral 
systems between specialised and mainstream health and social services is even more important 
for ageing drug users than for the general drug treatment population due to their complex needs 
(EMCDDA, 2010; Department of Health [no date]). The police, prisons and probation also need 
more training on the specific needs of older drug users and on how to link with other services 
(Hayes et al., 2012).  
 
 
Challenges for the user and the role of other services  
3.19. Caring for the ageing cohort of drug users requires highly skilled workers who can deal with 
the complexity of health and social care needs with which the ageing cohort of drug users is likely 
to present (Scottish Drugs Forum, 2017a, 2017b). As well as providing a full range of services and 
interventions focused on drug use, there is also a need for housing support and improving access 
to appropriate health services for this older age group (PHE, 2013). 
 
                                            
5 ‘There were significant increases in the proportion of individuals (aged 18 and over) leaving successfully for all substance 
groups between 2007–2008 and 2011–2012. Since then the rates have levelled off, with a decline in the proportion of opiate 
users completing treatment. This decline is likely to be in part because many of those who now remain in treatment for opiate 
use are older; and often have health and mental health problems and entrenched lifestyles and drug dependence’ (Burkinshaw 
et al., 2017: 34). Opiate users tend to be much older than those in treatment for other drug problems in prison-based drug 
treatment (ibid: 36).  
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3.20. The ageing cohort of drug users suffers from multiple disadvantages. These complicate their 
access to services, such as housing, dental care, hospital clinics, counselling and welfare 
benefits/social security. Although contact with primary and secondary healthcare services may 
provide an opportunity to screen ageing drug users, substance use disorders among older people 
may often be missed or misdiagnosed (Crome and Bloor, 2005). Owing to these complex needs, 
professionals working in this field have long recognised the value of multidisciplinary team work. 
As the 2017 PHE/RCN report noted, a varied skill mix is required in the workforce to respond 
adequately. Furthermore, as a PHE 2014 report noted, individuals with the most severe problems 
and complex needs will usually require close liaison with a range of other services. This liaison 
will, at times, require expert analysis and authoritative liaison by an addiction specialist. vi 
 
3.21. Drug services thus need a workforce skilled in the complexity of need among older drug users, 
covering not just substance use, but common comorbidities. Non-drug services, that are generic 
and other specialist health and social care services, need skills to detect drug use in the older 
population and awareness that some of their service users may be long-term substance users. 
 
3.22. Some service providers consider that the outcomes expected of mixed-age services are 
problematic for ageing people with long-term substance misuse problems, for whom abstinence 
may not be a realistic goal (evidence provided by stakeholders during the evidence gathering 
session, including from the Bristol Drugs Project). Participants in a consultation by DrugScope 
considered that for some long-term heroin users, care and treatment, and addressing long-term 
medical conditions, were the most appropriate outcomes (DrugScope/Recovery Partnership 
2014). 
 
Solutions  
3.23. Treatment outcomes may be improved further if treatment is delivered by a substance misuse 
service specifically for ageing people (as indicated by examples, such as programmes operated 
within services like those at the Bristol Drugs Project). However, few of these services exist in the 
UK and most that do exist are only commissioned to deliver alcohol treatment (Wadd and 
Galvani, 2014; Slaymaker and Owen, 2008).  
 
3.24. Several best practise examples of services for the ageing cohort and innovatory services exist 
(see Appendices, Appendix 3 and Appendix 4). The active ingredients of these examples include 
the following. 6  
• Person-focused interventions:  
o intensive case management;  
o helping clients to build their confidence;  
o encouraging physical activity;  
o helping clients to develop and maintain a social network; and, 
o providing a stable independent home combined with personalised support. 
 
• Service structures:  
                                            
6 These are all elements in a package of treatment and care to be devised appropriately for each individual 
case, taking into consideration the characteristics of that person’s social environment and available resources.  
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o comprehensive support package;  
o specialist older persons substance misuse service;  
o outreach services, and;   
o wrap-around services. 
 
• Service processes:  
o allowing service users to dip in and out;  
o meeting at the prison gate;  
o helping with navigating people from service to service; and,  
o outward facing services – engagement outreach and assertive outreach (Roy and Buchanan, 
2016). 
Best practise examples  
There are few services specifically directed for older drug users.  
 
In England, the Bristol Drugs Project’s ‘50 Plus Crowd’ is open to anyone aged 50 and over with drug 
and/or alcohol problems. Most using the service are on long-term methadone prescriptions with the 
BDP shared care team and have not been engaging with treatment services beyond these 
appointments. A twice-weekly group and regular social activities (swimming, yoga, dance therapy, 
gardening and walking) aim to help clients to develop and maintain a social network and build their 
confidence. Service users can ‘dip in and out’, attend social activities, and the group can be a route 
back into more structured treatment and engagement. 
 
WCADA has been providing a range of treatment interventions for those affected by substance misuse 
for over 30 years, originally from a single office in Swansea now with six agencies across Swansea, 
Neath Port Talbot and Bridgend. WCADA is one of the leading substance misuse treatment agencies 
in Wales, providing Minnesota 12-Step Abstinence treatment and Harm Reduction services, including 
needle exchange and outreach, targeted to individual need. Other services provided include 
information, advice and treatment for young people, older and disabled people, family members and 
carers.  
 
A comprehensive support package is available to older adults. It includes:  
• advice and awareness sessions;  
• health promotion; structured individual support and access to clinical alcohol; and,  
• drug treatment services, as appropriate, and wrap-around services, such as diversionary 
activities.   
Focus is placed on reducing isolation and supporting older adults to enhance their support network. 
 
In Wales, WCADA service users were asked ‘What Works Well?’ (APoSM, 2017).  
 
The following were included among the suggestions that were relevant to illicit drug users:  
• a friendly and welcoming atmosphere;  
• a non-judgemental approach where users are not stigmatised or criticised;  
• the central location of the service;  
• the availability of telephone support;  
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• regular contact with staff who understand;  
• support from family and friends; and,  
• an activities programme.7 
 
In Liverpool, a pilot programme was designed to improve the health of older high-risk drug users 
through exercise referral schemes. Resources were provided to encourage gym attendance (bus 
passes, sports clothing and membership fees). Improvements in self-esteem and confidence were 
noted (Beynon et al., 2013). There is a role for further development and innovations in encouraging 
physical activity among older illicit drug users (Neale et al., 2012). 
3.25. Knowledge about substance use and misuse among ageing drug users needs to be embedded 
beyond the obvious hospital specialties of emergency medicine, geriatrics and internal medicine, 
to include allied health professionals and general practice, who are often the first port of call 
when illnesses occur.8 There is a need for training of practitioners and integrating their services 
with the specialist drug services. Integrated and joined up support from a full range of generic 
and specialist interventions represents an opportunity to intervene earlier and more effectively.  
 
3.26. Training for staff working in drug and alcohol treatment services needs to be improved and 
expanded, especially given the loss of training posts with the run-down of addiction psychiatry 
(submission to consultation from the Royal College of Psychiatrists, see Appendices).  
 
3.27. Models of good practice with specialist nurse teams within hospital settings focusing on 
alcohol could be adapted for illicit drug users and evaluated (Ryder et al., 2010).  
 
3.28. There is a problem of misdiagnosis and inappropriate or no treatment among older drug users 
(Crome and Bloor, 2005, McGrath et al., 2005). The accurate diagnosis of high-risk drug use by 
the ageing cohort and addressing the various associated health issues will depend upon increased 
awareness and training of professionals and practitioners to support older high-risk drug users.  
 
3.29. One organisation representing treatment providers expressed the view that services need to 
fundamentally improve the referral systems between drug and alcohol treatment and 
mainstream health resources (submission from Collective Voice). 
 
3.30. Underlying the lack of appropriate responses and training is a lack of research and evaluation. 
There is a paucity of UK-based research and evidence for treatment interventions (Royal College 
of Psychiatrists, 2018). 
 
Challenges for users  
 
Stigma  
3.31. The ageing cohort is likely to experience considerable stigma when dealing with the general 
public and with services (Ayres et al., 2012; Wu and Blazer, 2011; EMCDDA, 2008; Conner and 
Rosen, 2008; Radcliffe and Stevens, 2008) and may have low expectations of health services 
                                            
7 These suggestions are also relevant for younger service users 
8 Geriatrics usually treat patients who are over 65 years.  
21 
 
(Beynon, 2009). Negative attitudes on the part of staff in specialist and in mainstream services 
get in the way of effective service delivery and deter attendance (Neale et al., 2008).  Women 
drug users are doubly stigmatised (EMCDDA, 2000; Taylor, 1993; Ettorre, 2007; Bows, 2015).  
 
3.32. Ageing chronically sick drug users are among those least able to navigate the complex 
pathways that make up the contemporary NHS and welfare systems (Hayes, 2016). Barriers for 
injecting drug users in general may relate to the burden of appointments, difficulties in travelling 
to services, stigma, negative staff attitudes, personal ill-health, lack of material resources and 
anxieties (Neale et al. 2008).9  
 
3.33. Care and support models that respond directly to issues of isolation and loneliness are 
appropriate. To respond to the issues of stigma and discrimination and to help in navigating 
services, advocates or service navigators are needed to ensure that substandard care is 
appropriately challenged and remedied. Transitions between various healthcare services are 
potential points for fragmented care and can be confusing and complicated for patients, formal 
and informal caregivers. These challenges are compounded for older adults with chronic disease, 
as they receive care from many providers in multiple care settings. System navigation has been 
suggested as an innovative strategy to address these challenges. The role of a navigator for the 
chronically ill older person is a relatively new one. There is some evidence that integrated and 
coordinated care guided by a navigator, using a variety of interventions such as care plans and 
treatment goals, is beneficial for chronically ill older adults transitioning across care settings. 
There is a need to further clarify and standardise the definition of navigation, as well as a need 
for additional research to assess the effectiveness and cost of different approaches to the health 
system (Manderson et al. 2012). There is scope for experimentation to apply this approach with 
regard to older drug users, especially the ageing cohort of opiate users. Service navigation has 
developed in cancer care and been employed to assist people with AIDS. Studies have observed 
a reduction in barriers, improvement in mediators, and improved health outcomes (Bradford, 
Coleman and Cunningham, 2007). Problems in accessing care by stigmatised groups such as Gay 
and Lesbian elders and their families have been noted (Brotman, Ryan and Cormier, 2003) and 
recommendations made include engaging in advocacy strategies, training, and outreach.  
  
3.34. Providing advocacy for the ageing cohort of drug users could be done through:  
• mainstream services for older people, such as Age UK;  
• by specialist drug services; or,  
• by mutual aid groups.  
(Wadd and Galvani, 2014). Specifically, the issue of accessing welfare benefits advice should be 
addressed.  
 
 
 
                                            
9 These mostly apply across all ages 
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4. Conclusions and recommendations  
For the purposes of this report, the ‘ageing cohort’ and ‘older drug users’ are considered to be aged 
over 35.  
 
Conclusions 
o Conclusion 1: Specialist community drug services are treating an ageing cohort of patients. 
Predominant among these are those with problematic opiate/opioid use.  
 
o Conclusion 2: Research suggests that older drugs users, particularly opiate/opioid users, have 
multiple additional risk factors resulting from their deteriorating physical and mental health, 
difficulty in navigating complex health and social care systems and experience of stigma. 
 
o Conclusion 3: There are indications which suggest that addressing the complex and varied 
needs of older opiate/opioid users will increasingly become a mainstream treatment activity. 
 
o Conclusion 4: Specialist community drug services are insufficiently prepared to manage the 
complex needs of this ageing cohort, despite the increase in older drug users attending for 
treatment.  
 
o Conclusion 5: Commissioners, providers and the specialist drug treatment workforce all need 
to ensure that staff are competent to meet these demands with the expected increase in 
complexity of treatment required by attendees. vii 
 
o Conclusion 6: Future trends in treatment presentations of ageing cohorts are difficult to 
predict and careful monitoring of drug treatment populations and other metrics of drug 
misuse should be explored and utilised. The better recording of prevalence of substance 
misuse by ageing drug users will improve understanding of the ageing treatment cohort and 
support service planning and delivery. 
 
Recommendations 
 
Recommendation 1: Specialist community-based drug treatment services should develop 
training for staff to highlight the treatments and specific risks for older drug users, 
particularly opiate/opioid users.  
Who is the recommendation directed to?  
Public Health England (PHE), with a specific request that they incorporate training into the 
current opioid substitution therapy (OST) quality improvement programme.  
Also applicable to: NHS England, Public Health Wales (PHW) and NHS Health Scotland and 
the Department of Health, Social Services and Public Safety (Northern Ireland), Royal 
colleges, commissioners and specialist community drug services. 
What metric would indicate that the recommendation had been implemented? 
The availability of a national learning package on the needs of older drug users along with 
evidence that this had been implemented by specialist community drug services. These 
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outcomes should be recorded and published, periodically reviewed and revised where 
appropriate.  
 
Recommendation 2: Given the changes to the specialist community drug treatment 
workforce over the last five years, an assessment should be conducted of the current range 
and availability of skills, treatment and support available to people presenting to treatment. 
A particular focus should be the availability and knowledge of staff to address the complex 
physical and mental health issues of older drug users. 
Who is the recommendation directed to?  
PHE, NHS England, PHW and NHS Health Scotland, Department of Health, Social Services and 
Public Safety (Northern Ireland), Royal colleges to conduct a review of the specialist 
community drug treatment workforce to determine whether the necessary expertise is 
available to treat the emerging needs of older drug users.viii 
What metric would indicate that the recommendation had been implemented? 
A published review of the workforce as part of a broader strategy to ensure that the workforce 
is skilled to meet the demands of an evolving treatment population. 
 
 
Recommendation 3: An evaluated pilot programme to determine whether the use of the 
service navigator model will assist older drug users to engage more successfully in complex 
health and social care systems, improve the quality of care and health outcomes and be cost 
effective. 
Who is the recommendation directed to? PHE, NHS England, PHW and NHS Health Scotland 
and the Department of Health, Social Services and Public Safety (Northern Ireland) 
What metric would indicate that the recommendation has been implemented? Published 
evaluation of service navigator model(s) to understand whether they are cost effective and 
improve the engagement of older drug users and improve the quality of care and health 
outcomes.  
 
 
Recommendation 4: Close and ongoing analysis of treatment presentation data and wider 
metrics of drug misusing patterns, with particular attention given to refining and 
standardising age categories.  
Who is the recommendation directed to? For surveys and collection of data by government 
agencies in Wales, Scotland and Northern Ireland; and more broadly, by others, especially 
researchers.   
What metric would indicate that the recommendation had been implemented? The 
standardisation of recording and presentation of age categories in prevalence of substance 
misuse data across the UK.  
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Appendix 1: Terms of Reference 
 
To explore the specific issues for older people (those aged over 35) with a drug problem focusing on 
those who have had a drug problem for an extended period of time. The Ageing cohort working group 
will work towards the following aims: 
 
• Using existing data to describe the demographics of the population in terms of age,  gender, 
location, morbidity and mortality and analysing this at different age bands; 35-44, 45-54, 55-64 
and over 65. 
 
• Projecting future demographics and needs for this population over a 10 and 20 year period. 
 
• Describing the present and likely future health and social care needs of this population. 
 
• Describing the nature and extent of present and future service demand of this population. 
 
• Identifying effective service responses including existing best practice. 
 
The working group will then make specific recommendations for practise and policy. 
 
Appendix 2: Working group membership 
 
ACMD members  
Mr Dave Liddell (co-Chair until December 2017)  
Dr Kostas Agath (co-Chair; Chair 2018-19) 
Professor Tim Millar  
 
Co-opted members 
Dr Caryl Beynon (Public Health England) 
Dr Gordon Hay (Liverpool John Moores University)  
Professor Susanne MacGregor (London School of Hygiene and Tropical Medicine)   
Maggie Telfer (Bristol Drugs Project) 
 
Secretariat  
Linsey Urquhart (Secretary to the Ageing Cohort working group until June 2018) 
Zahi Sulaiman (Secretary to the ACMD) 
Matthew Gavin (ACMD Secretariat)  
Imogen McHarg (ACMD Secretariat) 
 
 
 
 
 
 
33 
 
Appendix 3: Stakeholder consultation and methodology 
 
The working group wrote to stakeholders requesting written/oral submissions, addressing the 
following questions: 
Q1. What are the distinctive challenges older drug users (ODUs) face in terms of: 
a.    Mental health 
b.    Physical health 
c.    Wider social issues 
Q2. What are the distinctive substance misuse needs of ODUs with respect to: 
a.    Wider healthcare 
b.    Non-healthcare support 
c.    Criminal justice system 
Q3. What are the distinctive barriers ODUs face when accessing: 
a.    Healthcare services 
b.    Recovery services 
Q4. Could you share any practices that: 
a.    Appear to work well with ODUs 
b.    Have been less successful with ODUs 
Q5. Could you share any examples of commissioning addressing the needs of ODUs? 
Q6. Would the future needs of ODUs be different to the current ones? (If so, how?) 
Q7. Do you have experience of ODU groups? If so, which ones? 
 
Written Evidence was received from the following: 
 
British Association of Social Workers (Professor Sarah Galvani, Dr Wulf Livingston and Mr Trevor 
McCarthy)  
Bristol Drugs Project 
Collective Voice 
University of Bedfordshire (Dr Sarah Wadd) 
Her Majesty’s Chief Inspector of Prisons 
Making Every Adult Matter 
National Care Association 
Release 
Royal College of General Practitioners 
Royal College of Nursing 
Royal College of Psychiatrists 
The Salvation Army 
SMART Recovery 
 
Oral Evidence was received from the following at the Evidence Gathering Day: 
Collective Voice – Paul Hayes   
Making Every Adult Matter – Sam Thomas  
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Royal College of Psychiatrists – Professor Colin Drummond 
SMART Recovery – Angie King   
 
Project methodology 
A small working group, consisting of ACMD members and co-opted members with relevant 
experience (Appendix 2), convened to identify the scope and methodology of the project. During the 
course of the project, the working group held six meetings to consider the evidence and come to its 
conclusions and recommendations. 
 
Overview 
To deliver the terms of reference the working group analysed evidence collected from three 
complementary and sometimes overlapping routes: 
• a literature review;  
• a stakeholder consultation; 
• an analysis of a time-series of treatment data for England. 
 
Literature Review 
A wide range of literature was reviewed. This was a narrative rather than a systematic or 
comprehensive review, as the latter was beyond the resources available to the group. The working 
group did, however, search relevant databases of research literature (journal articles in particular) and 
access grey literature available on the Internet: this included documentary material (official reports) 
and publications by stakeholder groups. The group also searched international literature to provide 
some context for coming to their judgements but focused particularly on material from the UK. Overall 
there is a lack of research on this cohort in UK. However, the group’s approach was to triangulate 
evidence from published scientific works with administrative data and evidence from stakeholders 
before coming to their judgements.   
 
Stakeholder consultation  
The working group elicited stakeholder consultation through the submission of written evidence 
and/or participation in an evidence gathering meeting for the submission of oral evidence. To obtain 
the written evidence, in July 2016, a ‘call for evidence’ was issued to relevant stakeholders requesting 
comments on a set of questions listed at the beginning of this Appendix.  
 
Responses were received from 13 groups. 
To obtain the oral evidence, on 21 September 2016, an evidence gathering meeting was held attended 
by a number of stakeholder organisations. 
 
Limitations 
The project had a number of limitations that are worth discussing.  
 
35 
 
The terms of reference set the working group a very ambitious main task: to model the future 
demographics, health and social care needs and service demand of older problem drug users. The lack 
of substantial previous work in the area had meant that a number of compromises had to be made 
for this project to reach its main output – this report.  
 
In reviewing the extant evidence, the group drew on articles in peer-reviewed journals and peer- 
reviewed books and chapters. These numbered over 75. In addition, the group drew on data from 
government publications and data bases such as PHE. These numbered 22. Another source was expert 
syntheses and overviews, especially those of the ACMD: these numbered 11. The group also referred 
to findings reported in eight quality research reports from non-government bodies. A final source was 
commentary from informed stakeholders, numbering 17. This range of sources gave the group a 
thorough overview of the situation and key facts and issues. 
 
The working group would like to make the following four points.  
• Only a narrative rather than a comprehensive review was feasible given the limited 
membership and resources available to the group;  
• The group had to work with existing data and the definition of the population of interest had 
to be broad rather than narrow to maximise the flexibility in using relevant extant data. So, 
whilst the terms of reference were set to investigate issues faced by ‘people over 35 years 
with a drug problem over an extended period of time’; The extant literature has mainly 
addressed the issues of the opiate using population, although noting that polysubstance use 
is common. With the single exception of cocaine, very little is known about other forms of 
illicit problem use in older age. The resulting report therefore had an opiate focus.  
• Given the above, the group’s ability to generalise findings to non-opiate using populations 
with prolonged drug problems is limited. Crome et al. have provided the most comprehensive 
overview of Substance Use and Older People (Crome et al. 2015). This was the first book 
devoted to substance use disorders in older adults. The substances they considered include 
alcohol, illicit drugs and tobacco use. The book has a multinational focus. The ageing cohort 
of ‘problem drug users’ that this working group focused on is a subsection of the larger group 
of older substance users but they share some characteristics and needs that have implications 
for service configurations. Experience in clinical practice supports the view that this is a 
growing but neglected vulnerable group. The report Our Invisible Addicts encouraged greater 
attention to this age group (Royal College of Psychiatrists, 2011).  All these studies have 
emphasised the centrality of comorbidity in older age groups.  
 
The working group did, however, take seriously the views of experienced practitioners, service 
providers and their representatives as given through the consultation. These views were 
important in identifying key issues and priorities for attention.  
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Appendix 4 Issues raised in the consultation 
 
Bristol Drugs Project  
Research and experience at this project have identified key issues for drug users aged 55 years and/or 
older as:  
• A lack of access to services; and,  
• older users feeling out of place where the client group is predominantly younger.  
This group of people experience social isolation and have a range of needs relating to income, housing 
and stigma. They should be treated with compassion and sympathy.  
Long-term use can produce a feeling of hopelessness about any possibility of change and profound 
fear of both recovery (in a world where their recovery capital has shrunk) and continuing dependence 
into older age.  
It is important to recognise complexity. Clients suffer from a range of other conditions, as well as drug 
use and these can lead to problems, including the possibility of medication interactions.  
As drug use acts as a master status, other health issues can be overlooked or not recognised. Diversity 
within the group is often not recognised with other minority special needs being overlooked.  
The British Association of Social Workers (BASW)  
The British Association of Social Workers (BASW) added that there were specific needs relating to 
bereavement and early onset dementia. Other problems highlighted were with regard to residential 
placements where a person may fall outside either the commissioners’ and/or providers’ age range.  
There are a lack of services addressing co-existing mental health and substance use.  
Changes due to ageing may lead to reductions in tolerance resulting in unintended, and fatal, 
overdose.  
Other health issues include dental and respiratory problems.  
One major problem lies with the lack of identification of substance problems by front-line health and 
social care practitioners and this is particularly so with this marginalised age group. Hospital staff need 
education and support. There is concern about clinical and social responses to people entering the 
hospice system with alcohol and drug problems.  
There has been a systematic failure to give priority to addressing and working with alcohol and other 
drug use in mainstream social work.  There is a need for clinical and practice guidance for substance 
use and palliative/end of life care services with regard to working with people presenting with both 
conditions. These are currently being developed by Professor Sarah Galvani of Manchester 
Metropolitan University). [Galvani, 2015]. 
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There is a need for peer-led, rather than professional-led, recovery services, focused advocacy and 
partnership, and to ensure that existing guidance is followed. 
Collective Voice 
The experience of members of Collective Voice is that the overwhelming majority of premature deaths 
of those in treatment arise from the consequences of physical ill health rather than overdose.10 
Offenders, the homeless and people with mental health problems often have no GP.  In particular, it 
is regrettable that drug and alcohol treatment in prison has become disengaged from community 
provision; this presents real challenges to prisoners on release. Health and Well-being Boards are 
failing to deal with these issues.  
University of Bedfordshire: submission from Dr Sarah Wadd 
This research team have noted numerous examples of ageism in relation to substance misuse. These 
include:  
• Upper age cut-offs in substance use services which means that older adults cannot access 
them.  
• Older adults being excluded from clinical trials and intervention studies.  
• Drink and drug public awareness campaigns that are almost exclusively targeted at younger 
adults.   
• Older adults being excluded from national prevalence studies, for example, people aged 60 
and over are not asked about illicit drug use in the Crime Survey for England and Wales. Older 
adults (aged 75 and over) are not included in the national reporting of drug and alcohol 
treatment statistics (only recently addressed).  
• Older adults being less likely to be referred for treatment.  
• Ageist attitudes amongst professionals, for example, ‘they are too old to change their 
behaviour’ (this despite Dr Wadd’s analysis of treatment data that shows that older adults are 
more likely to be treated successfully for a drug problem than younger adults).  
The team suggests that there may be opportunities to nurture the types of peer support, community 
and voluntary activities that are one of the many strengths of the lesbian, gay bisexual and 
transgender (LGBT) communities.  
There is a need to extend training to people providing:  
• home care;  
• sheltered accommodation and care homes; 
• falls prevention services; 
• carer support services; 
• pain clinics;  
• older adults’ mental health services;  
• older adults’ social work teams; and,  
• volunteer befriending services. 
                                            
10 Recent research suggests that 75% of premature mortality among opioid users aged over 45 and under 65 
years is due to causes other than overdose, compared with 36% among 18 to 25 year olds (Pierce et al., 2015). 
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MEAM  
In addition to agreeing with the points made by others in the consultation, Making Every Adult Matter 
(MEAM) also noted issues around access to GPs and thus onward referrals. There is a lack of continuity 
of care. 
Release  
Release’s national helpline receives a worrying number of calls from older drug users, both in and 
outside of treatment settings. There is a lack of provision of quality psychological input alongside 
pharmacological interventions. Older drug users may experience death anxiety.  
It is Release’s experience that drug users needing large doses to relieve pain are often seen as engaging 
in ‘drug seeking’ behaviour. In addition, the prescribing of diazepam and other benzodiazepines 
among older patients is an important issue.  
Older service users may resent workers half their age, particularly ‘recovery champions’, telling them 
“if I can do it, so can you”. It seems distressingly common for long-term users to be told they have to 
cut down and come off, often on a first appointment in a new service.  
Release recommends that people are not forced into abstinence and that they are allowed to move 
away from, for example, regular pharmacy visits when this places an undue stress on them. Services 
might also recognise the achievement of a range of treatment goals, such as those defined by the 
client, perhaps in relation to what the general population view as ‘ordinary’ goals - personal, housing, 
good general health, and community involvement, - encompassing public health goals and responses 
that go beyond the imperative of people becoming ‘drug free’.  
There is a need for innovative services, such as sessional workers who could help clients with housing, 
benefits, learning computer skills and other interventions. 
Royal College of General Practitioners and Substance Misuse Management in General Practice  
The Royal College of General Practitioners and Substance Misuse Management in General Practice 
(RCPG/SMMGP) observe that it is possible that a significant number of drug-related deaths may not 
be accidental overdoses but have a degree of intent, something that should be explored and 
researched.  
Commissioners must start to plan for the care of problem drug users who are unable to leave their 
home, who might need, for example, home help services and the delivery of substitute medication. 
This group has specific accommodation needs.  
The new ‘Orange Guidelines’ 11 have specific information regarding pain management and older drug 
users and should be used as the basis of good practice. Increasing awareness of these guidelines 
should be undertaken to improve compliance.  
                                            
11 https://www.gov.uk/government/publications/drug-misuse-and-dependence-uk-guidelines-on-clinical-
management 
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There is also a need for provision to support a dignified death without discrimination. 
Royal College of Nursing  
The Royal College of Nursing (RCN) notes that all discussions on service needs have to take into 
account the context of reduced capacity in health services.  
The Royal College of Psychiatrists  
The Royal College of Psychiatrists (RCPsych) emphasises that older drug users often use alcohol, 
nicotine and over the counter medications as well as illicit drugs and prescribed medication. 
‘Substance use’ must be looked at in the broadest sense. Furthermore, a more substantial evidence 
base with regard to older people is needed.  
 
The second edition of their report ‘Our Invisible Addicts’ (Royal College of Psychiatrists, 2018) 
concluded that comorbidity was the key feature and that the problem can be best addressed 
through an approach that is multi-professional, involving psychiatry, nursing, pharmacy, 
occupational therapy, psychology, social work and the voluntary sector (including peer support). This 
matches with this report’s conclusions. They also concluded that there is a need for best practice to 
be implemented and extended to all relevant settings including the criminal justice system and end 
of life care.  
 
The RCPsych also stated that there was a paucity of UK-based research and evidence for treatment 
interventions and services relating to the management of substance use disorders in older people. 
 
Furthermore:  
• future research requires standardisation of age range, diagnostic tools and assessment 
instruments, treatment options and style of delivery in order to enhance comparability.  The 
inclusion of older adults in all treatment intervention studies in substance misuse should be 
the norm. 
 
• due to a dearth of research, there is scarce specific evidence to inform policy decisions in older 
people who misuse substances. There is a lack of research on policies that specifically target 
the older person’s substance misuse and associated harms. 
The Salvation Army  
The Salvation Army’s service user group (largely within the Homelessness Services) comes from a 
diverse age range, the majority of whom are under the age of 50. However, they are seeing an increase 
in those above this age entering Lifehouses (homeless hostels) and indeed treatment services. An 
individual with a substance issue is often perceived to be a nuisance and thus turned down for housing.  
Short time-bound treatment programmes can often be unsuitable for this client group as issues are:  
• often entrenched;  
• complicated with physical ailments; and,  
Support networks need to be established so that recovery is not just short-term. 
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SMART Recovery  
Smart Recovery regrets that the constant round of commissioning services leads to a lot of short-term 
planning and thinking in service delivery. There is huge pressure to deliver ‘results’ which could make 
it very difficult for organisations to respond to the needs of groups, such as older people with 
addictions, who are the least likely to engage in service user forums or representation to get their 
voices heard. 
 
Appendix 5: Extracts from recommendations of other expert bodies  
 
The DrugScope/Recovery Partnership 2014 
 
This collaboration recommended, among other things, the following in their briefing report It’s about 
time: Tackling substance misuse in older people (Drugscope/Recovery Partnership, 2014).  
 
• For policy and decision-makers 
Substance misuse issues of various kinds affect a significant number of older people. This needs to be 
recognised and addressed in the development and implementation of national policies and outcomes 
frameworks, including those focused on generic health and social care provision for older people. 
 
Drug problems among older people also need to be considered by decision makers at a local level and 
addressed in local health and wellbeing and older people’s strategies.  
 
At a local level, there is a diverse membership of Health and Wellbeing Boards – including Directors of 
Public Health, Clinical Commissioning Groups and Directors of Adult Social Services. This provides an 
important opportunity for the development of support and treatment pathways for older people with 
substance misuse problems as well as integrated services that recognise the range of needs they may 
have (for example, those who also have mental health problems, including people with dementia and 
Alzheimer’s). 
 
Older people with substance misuse problems are not a homogenous group. A range of interventions 
are therefore needed, such as age-appropriate, non-time limited treatment and support for those who 
are drug dependent.  
 
A range of outcomes will be appropriate for older people with drug problems, including recovery 
outcomes for some of those with more serious problems, and a wide range of other outcomes focused 
on improved health and increased levels of wellbeing. 
 
Options for sustainable funding need to be considered particularly as research indicates increased 
prevalence and need. 
 
• For substance misuse services 
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A range of measures can be implemented to help to ensure the accessibility and relevance of services 
for older people, including specific groups or times for older people, satellite services operating out of 
community provision aimed specifically at older people, for example, local support groups – and home 
visits. 
 
Social activities and events, as well as regular support groups should be developed. Service user 
consultation and involvement is crucial in the development of this provision. Substance misuse 
services also have an important role to play in supporting older people into meaningful engagement, 
such as volunteering, within their local community. 
 
The use of peer support, from ‘real peers’, can cut across the stigma that some older people with drug 
problems experience, helping them to feel more comfortable in a service and providing examples of 
positive change. Peer mentors can provide support in a range of ways, including emotional and 
practical support on a one-to-one basis and by facilitating groups and social activities. Providing 
support as a peer mentor can also help older people who have had substance misuse problems in the 
past to sustain the changes they have made in their lives. Consideration and provision of appropriate 
levels and kinds of support for peer mentors is important. 
 
There is a need for appropriate training for substance misuse practitioners on the particular needs of 
and issues faced by older people with drug and/or alcohol problems. 
 
• For older people’s services 
Older people with substance misuse problems may come into contact with a number of health and 
social care professionals, including those working in primary care settings, older people’s mental 
health services, residential services, and social care providers. There is a clear need for awareness 
raising and training of these professionals so that they are able to identify and assess substance misuse 
issues. 
 
EMCDDA 2008; 2010 
These two reports from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
identified the following issues for older people.  
• Substance use programmes for older adults should be able to provide basic-level medical 
services. 
• Where severe or complex health problems are identified, referral should be to specialist 
medical services. 
• Detoxification may be best conducted in a medical setting to avoid potential interactions 
between medications and other substances, or because of comorbid illnesses. 
• Different dose regimens may be required because of age-related metabolic changes. 
• As many therapeutic issues are poorly understood regarding ageing drug users, improved 
assessment of substance use disorders among older adults may require age-specific measures 
of use and dependence. 
• Appropriate and effective treatment should be tailored to the specific needs of older drug 
users, even if little is currently known about this patient group. This may require modifying 
existing forms of treatment or developing new ones. 
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• In particular, treatment should be more attentive to comorbid health conditions faced by 
older adults. 
• Although the identification of substance use disorders may be difficult, primary care and 
other healthcare services are well placed to screen for substance use problems. 
• Integrating geriatrics in drug treatment staff training and raising awareness about drug 
addiction among mainstream health providers for the elderly could be important starting 
points. 
• Older citizens should have access to effective healthcare services, where they will be catered 
for with dignity and sensitivity. This may require developing a wider range and alternatives to 
current treatment. 
• The prevalence of illicit drug use by older adults is increasing. Addiction treatment and other 
healthcare services are insufficiently aware of the needs of older drug users and need to 
anticipate and prepare for predicted increases in demand from this age group. 
• Improved assessment of substance use disorders among older adults may require age-specific 
measures of use and dependence.  
• As a consequence of the multiple problems experienced by older drug users, a joined-up 
treatment and care approach with effective interagency partnerships and referrals systems 
between specialised and mainstream health and social services is becoming more important 
than ever.  
 
 
Public Health England (Burkinshaw et al., 2017)   
The proportion of older heroin users, aged 40 and over, in treatment with poor health has been 
increasing in recent years and is likely to continue to rise. An ageing cohort of heroin users (many of 
whom started to use heroin in the 1980s and 1990s) is now experiencing cumulative physical and 
mental health conditions. Older heroin users are also more susceptible to overdose. It is important to 
help these people access to appropriate general healthcare services. All indications suggest that it is 
challenging to help people with complex needs and a long treatment history to achieve recovery. 
 
PHE recommend that policy and practice should incorporate the following.  
• Maintain a realistic recovery ambition for the ageing cohort of heroin users with complex 
needs, accepting that the proportion of people who successfully complete treatment is likely 
to continue to fall.  
• Provide longer-term employment and housing support, including in-work support, to help 
people to gain and maintain employment and appropriate housing.  
• Develop strategies to address the recent increases in drug-related deaths, including 
integrating healthcare with drug treatment for people who use drugs and improving local 
processes for reviewing incidents. 
• Ensure that there are arrangements to meet the physical and mental health needs of people 
who use drugs, particularly for older people in treatment.  
• Outcome expectations need to be cognisant of the fact that the proportion of older heroin 
users in treatment with poor health has been increasing in recent years and is likely to 
continue to rise. It may be challenging to help people with complex needs and a long 
treatment history to achieve recovery, but it is vital to help them to access appropriate 
healthcare services as a vital step in the process. 
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Scottish Centre for Crime and Justice Research (Atkinson, 2015) 
• Need for age-specific services. There is a requirement to specifically design or adapt services 
– either existing or bespoke – in order to effectively engage with older high-risk drug users. 
• Co-presence of physical and mental health issues.  Older high-risk drug users may have mental 
health issues in addition to their use of illicit substances. Additionally, the use of illicit 
substances may also have an adverse impact on their physical health. Such issues must be 
considered when devising and delivering effective service responses, which must tackle the 
range of issues in a holistic manner.  
• Exercise-focused interventions. There is indication in the research of some positive effects of 
exercise on the health and well-being of high-risk drug users of all ages, including older people. 
However, the results of the literature review also indicate barriers to the effectiveness of 
service responses to older high-risk drug users.  
 
 
Scottish Drug Forum 2010 
The guidance provided in Senior Drug Dependents and Care Structures Scotland: Guidelines for Service 
Responses was derived from the Senior Drug Dependents and Care Structures in Europe project work. 
 
• Need for future planning  
The proportion of older drug users among problem drug users in Scotland continues to grow and will 
require careful planning to meet future needs as the population ages further. Specialist services need 
not be set up to meet the specific needs of older drug users as their needs can be met by adapting 
existing non-age specific services. However, the development of innovative treatment and psycho-
social support approaches that might specifically benefit this population such as Housing First models 
[cf CSJ 2017] and heroin prescribing for those who fail to engage with other services and age specific 
group work should be explored.  
• Social networks and isolation and mental health  
Services and commissioners must take account of issues of isolation when planning and delivering 
services to older drug users. The breakdown of social networks and isolation is a major feature of older 
problem drug users as a group and these impact significantly on users’ well-being and their ability to 
be motivated to change their behaviour. There is a significant level of mental health problems within 
the drug using population. These appear to be particularly acute for older problem drug users often 
linked to or exacerbated by isolation and loneliness. It is thought by services that a significant number 
of the drug related deaths may not be accidental overdoses but have a degree of intent.  
 
• Therapeutic relationships  
Services for older drug users should place greater emphasis on forming meaningful therapeutic 
relationships as these are particularly important for this age group.  
 
Given the high levels of isolation and loneliness among this population, it is evident that relationships 
between workers and users are of even greater significance than those with younger users. For many 
individuals, such relationships may be the most significant relationships in their lives.  
 
A significant proportion of older drug users are isolated and lonely. However, services felt there was 
an opportunity to provide a role within families, for example caring for grandchildren.  
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Services should explore with older drug users if there are opportunities to re-engage with their families 
which could provide useful and supportive child care and reduce isolation.  
 
• Accommodation needs  
The Housing First model being developed in Glasgow should be explored for other parts of Scotland 
beyond Glasgow.  
 
The specific accommodation needs of older problem drug users require attention:  
• for those who are attempting to break away from their former drug using networks; or, 
• are likely to continue using drugs and require accommodation with a tenure that is not 
threatened by their continued drug use.  
 
• Relapse and alternative coping mechanisms  
Services should recognise the importance of relapse prevention and encourage ‘new coping 
mechanisms’. Older drug users, due to the length of their drug problem, have nearly all had periods 
of abstinence and stability followed by relapse or more chaotic use. It is not safe for services to assume 
that persons at the early stage of recovery are not at risk of relapse. Services report that older drug 
users have learned coping mechanisms for dealing with crisis and these tend to be drug use. The 
importance of providing new coping mechanisms was highlighted. These included:   
• support/peer groups; 
• alternative therapies;   
• talking therapies; and, 
• and other meaningful activity.  
 
• Individualised services  
Services should be providing individualised services to all, with older users having a significant input 
to their treatment plan, including substances prescribed and supervision arrangements. Issues relating 
to drug users and substitute prescribing include issues of choice of substitute drug, dosage level, 
means of administration and supervision arrangements. Gender emerges as a particularly important 
issue with older drug users. Workers felt strongly that women were inclined to rush through services 
while men on the other hand tended to move more slowly than necessary. Services need to 
acknowledge these gender issues which appear to be particularly apparent with older users. This could 
involve ensuring that women are encouraged to look at taking small steps with realistic goals, while 
men should be encouraged to focus more on long-term goals. 
 
• Innovative treatment approaches  
There is a need for services and planners to explore innovative approaches that might prove 
particularly attractive and relevant for older drug users as many have failed to engage with existing 
services. Innovative approaches might include assertive outreach for those dropping out of services. 
There is an evidence base for prescribing of injectables including heroin for those who have found it 
difficult to move away from injecting, particularly older users.  
 
•  Physical Health  
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There is a need for services working with older drug users to ensure, as far as practicable, that an 
individual’s general health care needs are met effectively. Services report significant evidence of major 
health impairment among older drug users which will get significantly worse over the coming years. 
In particular, blood borne viruses, respiratory and dental health problems. A range of physical health 
problems are becoming more apparent among older drug users. As part of this, pain management 
emerges as a particular issue that does not appear to be being dealt with effectively.  There is a need 
to improve pain management for older drug users. The ‘Orange Guidelines’ provide information for 
health staff regarding pain management and should be used as the basis of good practice. Awareness 
of these guidelines should be raised to improve compliance. There will be an increasing proportion of 
older problem drug users who will require care at home as a result of impairment of physical health. 
Services and particularly community services, must start to plan for the care of problem drug users 
who are unable to leave their home – in particular home help services and the delivery of any 
substitute medication.  
 
•  Late onset injecting drug use  
Services should not assume that older drug users all have a lengthy drug problem, greater than 15 to 
20 years. Although most will, there is a significant proportion that have developed a drug problem 
later in life. The drug problem may be less entrenched as a result and could necessitate different 
responses. The study has identified that the late development of injecting drug use is a surprisingly 
common phenomenon with vulnerable adults developing drug problems later in life (over 40 years 
old).  
 
• Staff training and awareness  
Training emerges as a significant issue if effective responses are to be delivered to the growing needs 
of older problem drug users over the coming years. Services should develop and support staff so that 
their services can be more responsive to and understanding of the specific needs of older drug users. 
Clearly all drug service staff should have the ability and skills to work with older drug users. However, 
in addition, there may be members of staff who have a particular understanding, awareness and 
empathy with older drug users. Means should be found to share this understanding and awareness.  
 
Scottish Drugs Forum (2017) Older People with Drug Problems in Scotland: Addressing the needs of an 
ageing population 
 
Among people with drug problems, those aged over 35 will become the main client group in specialist 
services for the foreseeable future.  They will also be a significant challenge to a wider range of services 
that will increasingly be required to offer help and support.  Therefore, in terms of planning for the 
future, Older people with drug problems’ (ODPD) complex and long-term care needs must be taken 
into consideration in the planning and development of all health, social care and related services.   
OPDPs are often doubly disadvantaged in terms of their general health.  They are generally drawn 
from the most deprived communities in Scotland where they grew up as children and adolescents and 
may have numerous consequent health inequalities.  Furthermore, they may have spent most of their 
adult lives dependent on illicit drugs and have lived an associated lifestyle that can have a very 
negative impact on general health. It is evident that current strategic planning of health and social 
care services has not adequately taken account of this group, or the consequences of their ageing, in 
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terms of service demand. At present, services, commissioners and planners, as well as Scottish society 
more widely, are generally unprepared to meet the care and support needs of this older drug-using 
population. 
 
Within specialist drug and alcohol services, there needs to be a focus on ensuring services that are 
geared to the needs of OPDPs so that the best outcomes can be achieved, ensuring people are safe, 
stable, have a good quality of life and are engaged with relevant services, reducing the frequency of 
unplanned hospital admissions for this group. The role of GPs in identifying, screening and treating 
this population is crucial. This role needs to be recognised and supported. The role of community 
pharmacists also needs to be explored as a means to screen for and manage long term conditions such 
as chronic obstructive pulmonary disease (COPD) and Hepatitis C. 
 
Pain management emerged as a major theme both for chronic and acute conditions for OPDPs. 
 
The majority of those surveyed had accessed services but length of stay in treatment was surprisingly 
short. 
 
The Scottish Drugs Forum’s Workforce Development Team has developed a training module on 
working with OPDP. 
 
Wadd and Galvani 2014 
The submission from Dr Wadd and Professor Galvani included the following suggestions:  
• Increase knowledge about what works in the identification, treatment and prevention of drug 
problems in older people and improve the collection and reporting of data;  
• Increase professionals’ competencies and skills in identifying and working with older people 
with drug problems;  
• Develop and test approaches to increasing older people’s ability to cope with stress and 
adversity (resilience) which can contribute to some people starting, returning to or escalating 
drug use in later life;  
• Scale-up and roll out an intervention that has been shown to be effective in identifying and 
treating medication addiction; and, 
• Broaden the remit of existing specialist alcohol services for older people to include treatment 
for drug problems and commission new integrated alcohol and drug treatment services for 
older people.  
 
The Welsh strategy (2008) ‘Working together to reduce harm: the substance misuse strategy for 
Wales 2008-2018’  
The Welsh strategy ‘Working together to reduce harm: the substance misuse strategy for Wales’ 
recognises the importance of addressing the particular needs of older people. It recommends the 
following.   
• Expanding outreach and harm reduction services.  
• Doing more to engage priority and hard to reach groups.  
• Identifying and minimising barriers to accessing treatment (including ensuring that all services 
can be accessed by those with physical disabilities).  
• User focused services that meet the needs of a range of specific groups.  
• Engaging substance misusers in the planning and design of services.  
• Improving the understanding of health and social care professionals.  
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• Providing diversionary activities (for example, volunteering, day services and leisure pursuits).  
 
 
Appendix 6: Summary of some relevant studies and innovations 
 
Addaction projects 
Addaction report on innovations to address the health needs of increasingly vulnerable service users. 
In Liverpool, it piloted a scheme that tested opiate users for respiratory problems, identifying 
hundreds of people who were unaware they had emphysema and referring them for treatment. In the 
South West, another pilot with the Hepatitis C Trust was successful in testing, treating and supporting 
people with Hepatitis C. Addaction also consider that the wider availability of naloxone has played a 
key role in saving lives of people who have overdosed. 
 
Dublin assertive case management project 
In Dublin, a multi-agency team focused on addressing the needs of a cohort of people with complex 
and multiple needs in the city centre (Dolphin, 2010). The team provides intensive case management 
support to people identified as members of the target cohort. The Anna Liffey Drug Project (ALDP) 
employs a team leader and a project worker using Health Service Executive (HSE) funding and provides 
management and volunteer support from existing resources. The two paid ALDP staff are the only 
members of the team who carry cases. They receive regular supervision from the ALDP head of 
services. The Garda have two members, one from each side of the city, allocated to working with the 
team. They give up roughly a quarter of their time each to the project, amounting to half a full-time 
input. Dublin City Council (DCC) provide the team with rent-free office and meeting space and 
resources. The Higher Level Group (HLG) is made up of senior management from: the HSE; the DCC; 
the Garda; and Dublin Region Homeless Executive (DRHE). The HLG meets every four-six weeks with 
the ALDP director in attendance to give an update on the project. An interagency case management 
team meeting takes place every week with the ALDP team leader and project worker, the Garda 
members and a Housing First representative. This meeting updates information and reviews all cases 
and identifies actions to progress cases. The team also has regular informal and/or structured 
communication with a range of other statutory agencies and community/voluntary charity/non-
governmental organisations (NGOs) providing services in the homeless and addiction sectors. The 
team focuses on conducting assertive case management in the city centre area by identifying, 
approaching, engaging with, and assisting those individuals with complex and multiple needs. The 
needs of the target group span four key areas: addiction and public injecting; homelessness and rough 
sleeping; anti-social behaviour, begging and criminal behaviour; and mental health. 
 
A cornerstone of the assertive case management team (ACMT) model is the consent protocol that 
clients are encouraged to sign up to before being taken on as full cases. This allows for exchange of 
information between different agencies, including the Garda, to progress case management. The 
following soft and hard outcomes were particularly highlighted during interviews:  
• emotional support to clients;  
• giving hope to clients, positive thinking and problem-solving through care plans;  
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• doing hand-holding for example, helping with paperwork, accompaniment, advocating in 
relation to other services, which solves practical problems for the client and therefore 
reinforces trust and engagement;  
• more rounded and informed assessment of client needs through interagency case 
management, leading to more comprehensive treatment plans;  
• clients supported to access services previously unavailable to them or excluded from;  
• better coordination of two specialisations - addiction and housing - to meet needs of clients;  
• more clients keeping medical and legal appointments;  
• clinics using the ACMT to follow-up on clients who drop out of medical treatment;  
• significant improvement in the relationship between many clients and the Garda, leading to 
increased communication, trust and compliance with the law, warrants and court 
appearances; and,  
• a reduction in drug-dealing, begging and anti-social behaviour. 
 
Improvements might be through the following.   
• the establishment of a crisis stabilisation/detox service for low threshold clients;  
• the establishment of protocols and practice for fast tracking those engaged in ACMT into 
housing and treatment options; and,  
• implementation of government policy on injecting rooms.  
(Dolphin, 2016). 
 
MEAM approach 
Between 2010 and 2013, Making Every Adult Matter (MEAM) supported a series of pilots to explore 
the better coordination of existing local services for people with multiple needs in three areas across 
England. These pilots were based in Cambridgeshire, Somerset and Derby, and focused on four core 
elements taken from previous multiple needs programmes:  
• coordination;  
• flexibility;  
• consistency; and,  
• measurement. 
 
There are seven core elements:  
• establish a partnership of the right people and understand local need;  
• establish a consistent referral process;  
• create a single point of contact to coordinate support for clients;  
• create flexible responses from partner organisations;  
• identify and fill any gaps in service delivery;  
• measure the impact on clients and the public sector economy; and,  
• embed change within the system so that improvements are permanent. 
 
The focus is on the better use of existing local resources. By 2016, 8 of the 11 areas had developed 
strong partnerships, found local funding, and were delivering coordinated interventions to adults with 
multiple needs in their local area. In Derby, the multiple needs service has continued in a slightly 
different format, integrated into the city’s substance misuse service. The principles of MEAM have 
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also helped to shape a programme of work on hospital discharge across the city. In Sunderland, a 
coordinator is based with the local substance misuse service, working directly with clients and 
influencing flexible service responses from local agencies. Norwich has established a partnership led 
by the Housing Department in the council, with representation from mental health, substance misuse 
and probation. The project is being coordinated by a local homelessness organisation. In Oxford, each 
client was assigned a ‘MEAM status’ allowing the client to access a small personalisation fund and 
additional hours of support from their existing key worker. 
 
Evaluation of the pilots (Barclay, 2016) concluded that the following strengths and issues were 
identified:  
• They liked the MEAM Approach, with its focus on those with most complex needs and 
improving coordination without being too prescriptive.  
• The support from MEAM’s Local Networks Team was well received and valued. Staff 
skills and experience in multiple needs, networking, communications, influencing 
policy and commissioners were cited as particularly helpful. Team members’ 
independence from the local area and local organisational politics was seen as a 
positive.  
• Local areas benefited from being part of a bigger network and the link to MEAM’s 
national policy influencing. 
• MEAM’s monitoring tool and workshops/support with monitoring and evaluation was 
perceived as useful. Links to MEAM’s national policy influencing helped 
coordinators/partnerships make the case locally and keep multiple needs/MEAM on 
local agendas.  
• One area told the working group that their MEAM work has identified some gaps 
where housing needs are not being met. This had led to them securing funding for 
three pilots relating to housing for people with multiple needs.  
• MEAM had to adapt to ensure addiction issues did not get lost from its work in the 
wake of DrugScope’s closure.  
• MEAM could highlight issues of concern around large reductions in funding 
drugs/alcohol support in parallel with an increase in mental health budgets, and 
increase awareness of the “false dichotomy” between mental health and addiction 
diagnoses.  
 
Nursing homes  
Elsewhere in Europe, a number of care and nursing homes have been piloted specifically for older drug 
users, however, there are concerns that they might increase stigmatisation and social exclusion and 
have a detrimental effect on maintaining abstinence for those who wish to do so (EMCDDA, 2010).   
 
With deteriorating health, limited social support and reduced mobility, many older problem drug users 
are faced with pressing accommodation and nursing needs. Due to the difficulty in accommodating 
older problem drug users in mainstream nursing or retirement homes, a few countries (for example, 
Denmark, Germany, the Netherlands) have developed specialised nursing homes and accommodation 
services for this group.  
 
Two of the first such care facilities for older drug users were developed as pilot projects in the late 
1990s in the Netherlands and Germany. The Dutch facility is part of an existing retirement home and 
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aims to cater for older drug users who are no longer able to look after themselves. Older drug users 
live in 24-hour supervised accommodation, where the aims include helping them to learn and 
maintain living skills, manage their income, monitor medicine use, engage in activities and follow a 
daily routine. The main goal is to help drug users live out their final years in comfort and dignity. An 
important point is that while residents are encouraged to reduce their drug use, consumption is not 
prohibited.  
 
The services provided within the German project comprise long-term residential care for older drug 
users and ambulatory forms of assisted living. Housed in living communities, older drug users can 
make use of outpatient drug treatment services and elder care. It is up to the project leader to decide 
on a case-by-case basis whether the services should be primarily geared to the need to treat 
dependence or to aspects of nursing care. In Germany, several such projects have now been 
implemented as pilot projects, though do not form part of the regular care offer.  
 
In 2004, the city of Copenhagen conducted a study of the needs for care and nursing facilities among 
persons over the age of 39 in substitution treatment and tried to assess their future care needs. The 
results suggested that about half of the users would start to need care and nursing services within five 
years. It was predicted that 76 % of them would experience somatic problems, 31 % mental disorders 
and between 30 % and 40 % social problems (social isolation, loneliness). The majority of older drug 
users lived in their own dwelling and were assessed to be capable of staying there with social support 
and care (home care, home nursing). A smaller share would need supported housing services that 
include supervision, social support, practical aid and care. Finally, due to their frailty, it would be 
necessary to place a significant number of older drug users in nursing homes.  
 
As a result, a series of ‘alternative nursing homes’ have been established throughout Denmark. The 
target clientele of these homes are “persons who, due to considerable and permanent physical and 
mental impairment of functions, need extensive help in ordinary, daily functions or care, nursing or 
treatment and who cannot get these needs covered in any other manner” (Section 108 of the 
Consolidation Act on Social Services). Alternative nursing homes provide the same services as 
traditional nursing homes, but must in addition be able to accommodate persons with an often more 
active and challenging behaviour than the mainstream nursing home patient. Also, besides satisfying 
the need for care, the aim of these homes is to create a social framework for users and prevent social 
isolation. 
 
Senior drug dependents and care structures (SDDcare) project (SDF 2010) 
The Senior Drug Dependents and Care Structures (SDDcare) project ran in four countries (Poland, 
Germany, Scotland and Austria) from 2008 to 2010 and was partly funded by the EU. It had the aim 
of:  
• creating a knowledge base on older drug dependents,  
• gathering data on the numbers involved,  
• their life circumstances and health situation, and,  
• their treatment and care needs.  
 
During this period, national experts compiled national and local epidemiological data from the 
participating countries, and information on the national legal and financial framework conditions 
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relevant to older dependent drug users. In addition, professionals, national experts and older drug 
users were interviewed in order to assess the treatment and care needs of this group of users. 
Examples of best practices in nursing homes and residential care in these countries were compiled. 
Finally, national experts from the participating countries drew up a set of national and European 
recommendations on the treatment and care of older drug users relevant to policymakers, 
researchers and professionals. 
 
In Germany, it is becoming clear that the most vulnerable older drug users, those most in need of 
support, have health and social comorbidities that are likely to be incompatible with full participation 
in the labour market. 
 
Linking drug users’ welfare support to their compliance with treatment has been shown in some 
studies to have potentially negative consequences. Drug users forfeiting their benefits were found to 
be, in the short term, more likely to turn to crime to fund their drug use. Older drug users may be 
particularly vulnerable to such sanctions, as their drug dependence is possibly more entrenched than 
that of young drug users. Alternative social reintegration policies and options may have to be 
developed for older entrenched drug users. 
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Appendix 7 – List of abbreviations used in this report  
ACMD Advisory Council on the Misuse of Drugs 
ACMT Assertive Case Management Team  
AIDS Acquired immune deficiency syndrome  
ALDP Ana Liffey Drug Project 
APoSM Advisory Panel on Substance Misuse  
BASW British Association of Social Workers  
BDP Bristol Drugs Project  
BPS British Psychological Society 
CMR Crude mortality rates  
COPD Chronic obstructive pulmonary disease  
CSJ Centre for Social Justice 
DCC  Dublin City Council  
DRDs Drug related deaths  
DRHE Dublin Region Homeless Executive  
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
Garda An Garda Síochána 
GP General practitioner 
HCV Hepatitis C virus 
HSE Health Service Executive 
ISD Information Services Division  
LGBT  Lesbian, Gay, Bisexual & Transgender 
MEAM Making Every Adult Matter 
NDTMS National Drug Treatment Monitoring System  
NGOs Non-governmental organisations  
NHS National Health Service 
ODUs Older drug users 
OPDP Older people with drug problems 
OST Opioid substitution therapy  
PHE Public Health England  
PHW Public Health Wales  
RCN Royal College of Nursing  
RCPG Royal College of General Practitioners  
RCPsych Royal College of Psychiatrists  
SDDcare Senior drug dependents and care structures 
SDF Scottish Drugs Forum  
SMD Substance misuse database 
SMMGP Substance Misuse Management in General Practice 
SMR Standardised mortality ratio 
WCADA Welsh Centre for Action on Dependency and Addiction 
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Appendix 8– ACMD membership 
Dr Kostas Agath Consultant Psychiatrist (addictions), CGL Southwark 
Dr Owen Bowden-Jones 
Chair of ACMD, Consultant psychiatrist, Central North 
West London NHS Foundation Trust 
Dr Anne Campbell 
Lecturer in social work and Co-Director of the drug and 
alcohol research network at Queens University Belfast 
Mr Mohammed Fessal Chief Pharmacist, CGL 
Dr Emily Finch 
Clinical Director of the Addictions Clinical Academic 
Group and a consultant psychiatrist for South London and 
Maudsley NHS Trust. 
Mr Lawrence Gibbons 
Head of Drug Threat – NCA Intelligence Directorate – 
Commodities 
Dr Hillary Hamnett Senior Lecturer in Forensic Science, University of Lincoln 
Professor Graeme 
Henderson 
Professor of Pharmacology at the University of Bristol 
Dr Carole Hunter 
Lead pharmacist at the alcohol and drug recovery 
services at NHS Greater Glasgow and Clyde 
Professor Roger Knaggs  
Associate professor in clinical pharmacy practice at the 
University of Nottingham 
Professor Tim Millar  
Professor of Substance Use and Addiction Research 
Strategy Lead at the University of Manchester 
Mr Rob Phipps 
Former Head of Health Development Policy Branch, 
Department of Health, Social Services and Public Safety, 
Northern Ireland 
Mr Harry Shapiro Director - DrugWise 
Professor Alex Stevens Professor of Criminal Justice, University of Kent 
Dr Richard Stevenson Emergency Medicine Consultant, Glasgow Royal Infirmary 
Dr Paul Stokes 
Senior Clinical Lecturer in mood disorders, King’s College, 
London 
Dr Ann Sullivan Consultant physician in HIV and Sexual health. 
Professor Matthew Sutton 
Chair in Health Economics at the University of 
Manchester and Professorial Research 
Professor David Taylor Professor of Psychopharmacology, King’s College, London 
Professor Simon Thomas 
Consultant physician and clinical pharmacologist, 
Newcastle hospitals NHS Foundation Trust 
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Dr Derek Tracy 
Consultant Psychiatrist and Clinical Director, Oxleas NHS 
Foundation Trust 
Miss Rosalie Weetman Senior Commissioning Manager of Substance Misuse 
 
 
 
 
 
 
ENDNOTES 
i In 1962, Winick, based on data from the Federal Bureau of Narcotics indicating a sharp decline in 
opiate misuse after the age of 36 years, hypothesised that a substantial majority of opiate addicts 
‘mature out’ of their addiction as a result of the normal ageing process (Winick 1962). Subsequent 
findings, however, have not supported a cause-and-effect relationship between chronological age 
and the cessation of addiction. Instead, it is now evident that addiction initiated in youth often 
persists into advanced age. 
 
ii For Figure 3 - NDTMS data on opiate users aged 35 and over in treatment, by local authority area can be 
found at: https://www.ndtms.net/  
 
iii Cf Davis et al. (2010) who observe that ‘Fibrosis progression was inversely related to age at 
infection, so cirrhosis and its complications were most common after the age of 60 years regardless 
of when infection occurred’ 
 
iv Speculatively; this could possibly be due to age-related effects on QTc prolongation &/or renal 
/liver impairment and/or other aspects of methadone pharmacology that are not yet fully 
understood. Increased prevalence of underlying heart disease is also a factor increasing risk from QT 
prolonging medications.  
 
v ‘Current data on the number of nurses employed in alcohol and drug treatment services is not 
available. However, stakeholders engaged in the development of this briefing reported that fewer 
nurses are employed in alcohol and drug worker roles than ten years ago’. (PHE/ RCN 2017: 5). 
 
vi Expert liaison work relating to delivering care for alcohol and drug users is likely to include:  liaising 
with relevant professionals to support delivery of recovery outcomes (including social care, criminal 
justice, housing, medical, psychiatric, employment, children and families professionals); working at 
the interface between alcohol and drug services and mainstream mental health; working at the 
interface between alcohol and drug services and the acute physical health sector, for example, 
treatment of blood-borne viruses and acute liver disease, cancer care, diabetes, managing the health 
complications of ageing and palliative care ; providing liaison alcohol and drug services in acute 
medical and psychiatric settings (PHE 2014). 
 
vii Professionals working within services, whether frontline workers, clinical leads or service 
managers are responsible for their own professional conduct and competence, and for the quality of 
care that they provide (PHE, 2014: 6). Local authority-based directors of public health have new 
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responsibilities to ensure that any clinical services they commission using the public health grant 
(including alcohol and drug services) have appropriate clinical governance arrangements in place 
that are equivalent to NHS standards (ibid).  
 
viii See also ACMD 2017 Commissioning impact on drug treatment, which includes the 
recommendation that ‘The Government’s new Drug Strategy Implementation Board should ask PHE 
and the Care Quality Commission to lead or commission a national review of the drug misuse 
treatment workforce. This should establish the optimal balance of qualified staff (including nurses, 
doctors and psychologists) and unqualified staff and volunteers required for effective drug misuse 
treatment services. This review should also benchmark the situation in England against other 
comparable EU countries.’  
 
